Table 1. Clinical and demographic characteristics of infants who received palivizumab versus control infants.
| Characteristics | Palivizumab group | Control group |
|---|---|---|
| Median age in months (25% percentile; 75% percentile) | 8 (5.5; 15) | 6.5 (4.25; 11) |
| Gender | ||
| • Male | 19 | 13 |
| • Female | 14 | 11 |
| RSV season | ||
| • 2013–14 | 17 | 24 |
| • 2014–15 | 16 | 0 |
| Number of doses received | ||
| • 1 | 1 | NA |
| • 2 | 1 | NA |
| • 3 | 7 | NA |
| • 4 | 23 | NA |
| • 5 | 1* | NA |
| Reason for referral | ||
| • BPD | 6 | NA |
| • GA <29 weeks | 7 | NA |
| • GA 29 to <35 weeks# | 4 | NA |
| • CHD | 6 | NA |
| • CF | 5 | NA |
| • Other | 5 | NA |
Controls were infants ≤12 months of age who did not receive any palivizumab. NA, not applicable; BPD, bronchopulmonary dysplasia; GA, gestational age; CHD, congenital heart disease; CF, cystic fibrosis;
*, infant received a 5th post-operative dose following cardiac surgery and prior to serum collection;
#, infants with a risk factor score ≥42 points. See Lavoie et al. [4] for details on the administration criteria and calculation of the risk factor score for palivizumab prophylaxis in British Columbia, Canada, during the 2013/14 and 2014/15 seasons.